GlassScriptPhysician profile
Su Ling Parker
NPI 1932214897
$1,756.21
in general payments reported to CMS, 2019-2025
26 companies · $250 in 2025
The $250 reported for 2025 was more than what a typical Obstetrics provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $372 · 2020: $131 · 2021: $424 · 2022: $384 · 2023: $96.23 · 2024: $98.61 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $445.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $444.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $457.65 | 2019-2022 | |
| Exeltis, USA INC. | $183.53 | 2021-2025 | Slynd |
| Hologic Sales and Service, LLC | $169.88 | 2019-2025 | Aptima, Novasure |
| Therapeuticsmd, INC. | $126.04 | 2019-2022 | |
| Amag Pharmaceuticals, INC. | $83.51 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $80.43 | 2021-2025 | |
| Pfizer INC. | $68.65 | 2019-2024 | |
| Avion Pharmaceuticals | $63.12 | 2021-2023 | Balcoltra |
| Myovant Sciences INC. | $50.00 | 2021-2022 | |
| Momentis Surgical INC. | $50.00 | 2022 | |
| Organon LLC | $48.38 | 2022-2023 | Nexplanon |
| Coopersurgical, INC. | $46.93 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $45.62 | 2021-2023 | Gardasil 9 |
| Evofem Biosciences, INC. | $43.68 | 2021-2022 | |
| Ascend Therapeutics US, LLC | $41.24 | 2020-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $30.92 | 2021-2023 | |
| Amgen INC. | $28.35 | 2019-2025 | Prolia, Evenity |
| Exact Sciences Corporation | $21.82 | 2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $20.71 | 2025 | Myfembree |
| Duchesnay USA Incorporated | $20.51 | 2019 | |
| Axonics, INC. | $17.11 | 2022 | |
| Laborie Medical Technologies Corp. | $16.82 | 2023 | |
| Astellas Pharma US INC | $16.01 | 2025 | Veozah |
| Lupin INC. | $13.31 | 2019 | |
| Agile Therapeutics, INC. | $11.99 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Su Parker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.